Moderna's Covid-19 vaccine gets authorisation in Australia for children
Moderna has reported that its Covid-19 vaccine, Spikevax (mRNA-1273), obtained provisional registration from the Therapeutic Goods Administration (TGA) in Australia for active immunisation to prevent Covid-19 in children of the age six to 11 years. The authorised dosage of the messenger ribonucleic acid (mRNA) vaccine is a 50µg dose to be administered as a two-dose regimen. Spikevax was analysed in the ongoing, observer-blind, randomised, placebo-controlled, expansion Phase II KidCOVE clinical trial.
Pharmaceutical Technology - February 17, 2022View the full story here: https://www.pharmaceutical-technology.com/news/moderna-vaccine-australia-children/